, 2025 Eccogene, Shanghai, China / AstraZeneca, Gothenburg, Sweden Elecoglipron (ECC5004/AZD5004) is an oral, small molecule GLP-1 receptor agonist with a biased signaling profile
doi:10.1016/j.placenta.2010.02.011
10.1038/s41386-018-0010-3 47 HernandezN
Blood 121 , 23112315 (2013)
The clinical results reflect what's possible when medication is paired with a reduced-calorie diet and increased physical activity, which is also how it's indicated for use in real-world treatment
Common reconstitution errors that cause reactions: Over-agitation: Shaking the vial vigorously creates foam and can denature the peptide, producing aggregated protein fragments that trigger stronger immune responses